CHARLOTTE, N.C., Jan. 23, 2008 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has initiated enrollment and patient dosing in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-1504 against methotrexate (MTX) in rheumatoid arthritis (RA) patients.
